Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCDA BioCardia	$1.92 +1.6%	$2.13	$1.63 ▼ $4.66	$11.14M	0.81	650,310 shs	86,681 shs
CANF Can-Fite BioPharma	$0.66 -1.6%	$0.94	$0.63 ▼ $3.12	$2.34M	1.02	211,613 shs	78,807 shs
IBIO iBio	$0.74 +9.3%	$0.75	$0.56 ▼ $6.89	$12.24M	0.6	1.40 million shs	1.39 million shs
PRTG Portage Biotech	$8.68 -1.4%	$6.46	$2.30 ▼ $23.01	$9.10M	0.24	46,079 shs	15,155 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCDA BioCardia	+1.59%	+7.26%	-15.04%	-21.31%	-25.87%
CANF Can-Fite BioPharma	-2.22%	-3.80%	-36.75%	-37.05%	-73.35%
IBIO iBio	+9.32%	+24.74%	+1.26%	-7.29%	-59.94%
PRTG Portage Biotech	-1.36%	-6.67%	+45.39%	+10.01%	+7,974.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCDA BioCardia	3.685 of 5 stars	3.8	5.0	2.6	2.5	0.6
CANF Can-Fite BioPharma	1.9774 of 5 stars	3.5	2.0	1.1	0.0	1.3
IBIO iBio	1.1947 of 5 stars	3.5	0.0	0.0	0.0	0.6
PRTG Portage Biotech	1.367 of 5 stars	0.0	5.0	3.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCDA BioCardia	3.50	Strong Buy	$25.00	1,202.08% Upside
CANF Can-Fite BioPharma	3.00	Buy	$14.00	2,018.00% Upside
IBIO iBio	3.00	Buy	$5.00	574.58% Upside
PRTG Portage Biotech	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CANF, BCDA, PRTG, and IBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/29/2025	CANF Can-Fite BioPharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/25/2025	IBIO iBio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCDA BioCardia	$60K	185.60	N/A	N/A	($0.33) per share	-5.82
CANF Can-Fite BioPharma	$674K	3.47	N/A	N/A	$1.76 per share	0.38
IBIO iBio	$375K	32.65	N/A	N/A	$1.41 per share	0.53
PRTG Portage Biotech	N/A	N/A	N/A	N/A	($0.79) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCDA BioCardia	-$7.95M	-$1.85	N/A	N/A	N/A	N/A	-19,117.42%	-246.92%	N/A
CANF Can-Fite BioPharma	-$7.63M	-$1.79	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IBIO iBio	-$24.91M	N/A	0.00	N/A	N/A	N/A	-73.15%	-45.51%	N/A
PRTG Portage Biotech	-$6.77M	-$41.65	N/A	∞	N/A	N/A	N/A	N/A	8/26/2025 (Estimated)

Latest CANF, BCDA, PRTG, and IBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/11/2025	Q2 2025	BCDA BioCardia	-$0.50	-$0.40	+$0.10	-$0.40	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCDA BioCardia	N/A	N/A	N/A	N/A	N/A
CANF Can-Fite BioPharma	N/A	N/A	N/A	N/A	N/A
IBIO iBio	N/A	N/A	N/A	N/A	N/A
PRTG Portage Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCDA BioCardia	N/A	0.33	0.36
CANF Can-Fite BioPharma	N/A	2.93	N/A
IBIO iBio	0.05	1.76	1.76
PRTG Portage Biotech	N/A	2.02	2.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCDA BioCardia	20.57%
CANF Can-Fite BioPharma	21.00%
IBIO iBio	7.90%
PRTG Portage Biotech	13.36%

Insider Ownership

Company	Insider Ownership
BCDA BioCardia	20.00%
CANF Can-Fite BioPharma	0.80%
IBIO iBio	0.58%
PRTG Portage Biotech	42.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCDA BioCardia	40	5.80 million	4.64 million	Optionable
CANF Can-Fite BioPharma	8	3.54 million	N/A	Not Optionable
IBIO iBio	100	16.52 million	9.82 million	N/A
PRTG Portage Biotech	6	1.05 million	608,000	Optionable

CANF, BCDA, PRTG, and IBIO Headlines

Recent News About These Companies

Portage Biotech (NASDAQ:PRTG) Stock Price Down 1.4% - Time to Sell?

August 16 at 3:49 AM | americanbankingnews.com

Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025

July 25, 2025 | globenewswire.com

Portage Biotech Regains Nasdaq Compliance, Maintains Listing On Capital Market | Nasdaq

June 27, 2025 | nasdaq.com

PRTG Portage Biotech Inc. - Seeking Alpha

June 26, 2025 | seekingalpha.com

Portage Biotech Inc. (PRTG) Income Statement - Yahoo Finance

June 26, 2025 | finance.yahoo.com

Portage Biotech Regains Nasdaq Compliance

June 25, 2025 | tipranks.com

Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements

June 25, 2025 | globenewswire.com

Portage Biotech Inc. (PRTG) Cash Flow - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Portage Biotech acquires stake in Compedica for $5 million

June 10, 2025 | investing.com

Portage Biotech and Compedica Forge Strategic Alliance with Stock Exchange

June 9, 2025 | tipranks.com

Portage Biotech Inc. Enters Subscription Agreement with Compedica Holdings Limited for Strategic Equity Investment

June 9, 2025 | quiverquant.comQ

Portage Biotech and Compedica Stock-for-Stock Exchange

June 9, 2025 | globenewswire.com

Portage Biotech Shares Rise on Confirmatory Trial Results, Plans for Human Trial

April 28, 2025 | marketwatch.com

Portage Biotech stock soars on promising preclinical results

April 28, 2025 | za.investing.com

Portage Biotech Stock Surges On New Preclinical Data In Mesothelioma Trial: Retail Gets More Bullish

April 28, 2025 | msn.com

Portage Biotech Inc. Reports Positive Preclinical Efficacy Data for PORT-7 at AACR Annual Meeting 2025

April 28, 2025 | quiverquant.comQ

Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7

April 28, 2025 | globenewswire.com

Insider Stock Buying Reaches US$2.15m On Portage Biotech

April 26, 2025 | finance.yahoo.com

Portage Biotech Inc. Common Stock (PRTG) Pre-Market

March 30, 2025 | nasdaq.com

Portage Biotech presents preclinical data for PORT-7

March 28, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CANF, BCDA, PRTG, and IBIO Company Descriptions

BioCardia NASDAQ:BCDA

$1.92 +0.03 (+1.59%)

Closing price 08/15/2025 03:59 PM Eastern

Extended Trading

$1.90 -0.02 (-1.04%)

As of 08/15/2025 07:50 PM Eastern

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

Can-Fite BioPharma NYSE:CANF

$0.66 -0.01 (-1.64%)

Closing price 08/15/2025 03:47 PM Eastern

Extended Trading

$0.67 +0.01 (+0.76%)

As of 08/15/2025 07:19 PM Eastern

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

iBio NYSE:IBIO

$0.74 +0.06 (+9.32%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$0.76 +0.02 (+2.27%)

As of 08/15/2025 07:58 PM Eastern

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

Portage Biotech NASDAQ:PRTG

$8.68 -0.12 (-1.36%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$8.82 +0.15 (+1.67%)

As of 08/15/2025 07:52 PM Eastern

Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time